The role of signal transduction in cancer treatment and drug resistance

被引:21
作者
Liem, AA
Chamberlain, MP
Wolf, CR
Thompson, AM [1 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland
[2] Univ Dundee, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland
[3] Univ Dundee, Biomed Res Ctr, Dundee DD1 9SY, Scotland
来源
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY | 2002年 / 28卷 / 06期
关键词
signal transduction; drug resistance; clinical trials; review;
D O I
10.1053/ejso.2002.1303
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Drug resistance in the treatment of cancer still remains a major clinical challenge, in part due to an insufficient understanding of the pathways by which these drugs interact with the mechanisms underlying cellular behaviour and cancer pathogenesis. Signal transduction involves cell differentiation, proliferation and cell death with alterations in these mechanisms being involved in the pathogenesis of cancer. It has been postulated that such pathways could be linked to anti-cancer drug resistance. Recently, novel approaches to overcome anti-cancer drug resistance through manipulation of signal transduction pathways, have been introduced in clinical trials. In this article we present a review of the current understanding in the field of signal transduction and the existing evidence for its role in drug resistance. We also discuss its clinical relevance with regard to overcoming drug resistance. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:679 / 684
页数:6
相关论文
共 84 条
  • [61] Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C
    Propper, DJ
    McDonald, AC
    Man, A
    Thavasu, P
    Balkwill, F
    Braybrooke, JP
    Caponigro, F
    Graf, P
    Dutreix, C
    Blackie, R
    Kaye, SB
    Ganesan, TS
    Talbot, DC
    Harris, AL
    Twelves, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) : 1485 - 1492
  • [62] Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer
    Pusztai, L
    Esteva, FJ
    Cristofanilli, M
    Hung, MC
    Hortobagyi, GN
    [J]. CANCER TREATMENT REVIEWS, 1999, 25 (05) : 271 - 277
  • [63] Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.3.CO
  • [64] 2-W
  • [65] Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt
    Rommel, C
    Clarke, BA
    Zimmermann, S
    Nuñez, L
    Rossman, R
    Reid, K
    Moelling, K
    Yancopoulos, GD
    Glass, DJ
    [J]. SCIENCE, 1999, 286 (5445) : 1738 - 1741
  • [66] Salituro FG, 1999, CURR MED CHEM, V6, P807
  • [67] Cell Signaling by Receptor Tyrosine Kinases
    Lemmon, Mark A.
    Schlessinger, Joseph
    [J]. CELL, 2010, 141 (07) : 1117 - 1134
  • [68] Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
    Sebolt-Leopold, JS
    Dudley, DT
    Herrera, R
    Van Becelaere, K
    Wiland, A
    Gowan, RC
    Tecle, H
    Barrett, SD
    Bridges, A
    Przybranowski, S
    Leopold, WR
    Saltiel, AR
    [J]. NATURE MEDICINE, 1999, 5 (07) : 810 - 816
  • [69] Development of anticancer drugs targeting the MAP kinase pathway
    Sebolt-Leopold, JS
    [J]. ONCOGENE, 2000, 19 (56) : 6594 - 6599
  • [70] Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies
    Sebti, SM
    Hamilton, AD
    [J]. ONCOGENE, 2000, 19 (56) : 6584 - 6593